Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS) - Tabular View

Tracking Information

First Received Date ^ICMJE

January 25, 2008

Last Updated Date

March 13, 2009

Start Date ^ICMJE

July 2007

Primary Completion Date

July 2007 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00610402 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

Official Title ^ICMJE

Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

Brief Summary

Sturge-Weber Syndrome (SWS) is a neurological disorder characterized at birth by seizures and a large port-wine stain birthmark on the forehead and upper eyelid of one side of the face. SWS is also accompanied by an increased pressure within the eye (glaucoma) which can develop very early in life.

Glaucoma represents a group of ocular disorders that are characterized by the loss of retinal ganglion cells and their axons, damage to the optic nerve, and gradual loss of visual field. Recently, several studies provided evidence that there is a potential role of the immune system in the pathogenesis of glaucoma.

These findings suggest that there might be changes in systemic humoral immunity possibly underlying the optic neuropathy in at least some glaucoma patients.

Detailed Description

The ocular antibody profile in patients with SWS is unknown.The researchers want to study on blood and tear drop samples from patients with SWS to determine the incidence of ocular antibodies in patients with this syndrome.

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Case-Only, Prospective

Condition ^ICMJE

Sturge - Weber Syndrome (SWS)

Intervention ^ICMJE

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

June 2008

Primary Completion Date

July 2007 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Male and female volunteers with SWS of all ages

Exclusion Criteria:

Volunteers without SWS

Gender

Both

Ages

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00610402

Responsible Party

J. Stuart Nelson, M.D., Ph.D. Associate Director and Medical Director at the Beckman Laser Institute and Medical Clinic, Beckman Laser Institute, University of California, Irvine

Study ID Numbers ^ICMJE

NIH-LAMMP P41-RR01192

Study Sponsor ^ICMJE

University of California, Irvine

Collaborators ^ICMJE

Mainz University

Investigators ^ICMJE

Principal Investigator:

John S Nelson, M.D,PhD

Beckman Laser Institute University of California Irvine

Information Provided By

University of California, Irvine

Verification Date

March 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP